We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go: Stretch investment: Withheld
Smartlands is a blockchain-based digital finance and investment ecosystem. It allows asset owners to turn an ownership right to a share of any asset, into a tradable digital token attributing it almost unlimited liquidity. In the UK, Smartlands is the first platform for crowdfunding investments that allows investors to use digital currencies alongside fiat currencies to raise capital. The platform boasts of a 16,000 strong community following with over 11,000 wallets opened since its inception. It has a reputed list of partners including Colliers International, CMS, Archax, UK Sotheby’s, and many more. They have been awarded the 'Best Crowdfunding Platform' at the 2020 FinTech Breakthrough Awards and have been featured in Yahoo Finance, Forbes, Coindesk, Benzinga, and Investors Chronicle to name a few. With the investment, the company will grow its internal engineering team and obtain the necessary licenses to move its business forward across Europe.

Pitch Rated

76%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £379,183
World of Expats is a business designed to support expats with the tools, services and information they need to make the most of their live as an expat.
days to go: Expired investment: £49,153
TheCarCrowd is a Passion Asset Investment (PAI) platform that intends to address the lack of investment options for the 8 million UK millennials by allowing them to take a real equity stake in a classic car and benefit from the potential appreciation. The company argues that classic cars appreciated 194% over 10 years up to Q4 2019 as per expert reports. TheCarCrowd points out that its portal allows interested investors to buy shares in cars from just £20 and unlock the benefits of potential appreciation. The company asserts that its business idea has found traction amidst users with over 620 investors registering on the portal since the company's launch in November 2020. TheCarCrowd will use 12% of the investment for Public Relations (PR), 48% for marketing, and 40% for working capital.

Pitch Rated

46%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £379,108
Fast-tracking ideas by connecting innovators and organisations together on a single platform. WorldLabs is helping the development of innovations by streamlining the process of those seeking funding and resources to make changes in the world. The company has already partnered with establishments such as UCL and Cambridge University. WorldLab's ecosystem is designed to assist innovators in raising awareness for their initiatives and collaborate with businesses that support the idea. To date, almost 7,000 members are signed up to the platform, with more than 1,000 live projects listed. Funds will be used to increase the number of partnerships with international universities and institutions, as well as develop a mobile app with sophisticated features such as machine learning algorithms.
days to go: Expired investment: £527,943
Clinical Net is a health-tech firm focused on revolutionizing access to innovative clinical trials. Their AI platform swiftly connects patients with suitable trials, addressing the challenge of low participation rates and delays that hinder pharmaceutical research. With over 69,000 trials globally, their solution aims to streamline the cumbersome and time-consuming process of trial matching, making it more efficient and accessible within 5 minutes. This innovative approach targets the $3.73 billion patient recruitment market while ensuring individuals have easier access to groundbreaking treatments.
days to go: Expired investment: £136,827
iBan Wallet has created an app which allows users to be in control of their finances, connecting them to the people involved in any transaction. They will create a space for investors and also for borrowers, allowing the borrowers to be in control of the amount of interest they pay. 
days to go: Expired investment: £111,648
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph